Comparison of Effect & Safety of Clopidogrel Napadisilate With Clopidogrel Bisulfate in Coronary Artery Disease Patients

Inclusion Criteria: * aged 20 to 80 years * men and women with coronary artery disease who had been treated with drug-eluting stent placement before \> 12 months * patients who had remained in a stable condition with a single antiplatelet agent, aspirin * patients who did not show any sign or symptom of the worsening of their angina within the last six months that required a coronary artery intervention, a coronary artery bypass, or coronary angiography Exclusion Criteria: * Patients who were taking another antiplatelet or anticoagulant drug such as clopidogrel, warfarin, or cilostazol in addition to aspirin, unless they could withdraw from such other drug/s, in which case they could be enrolled in the study after a two-week wash-out period * Patients who were suffering from drug abuse or alcohol addiction * hypersensitivity to clopidogrel or aspirin * severe liver disease (ALT or AST ≥ 10 times the upper normal limit) * active hemorrhage such as gastro-intestinal ulcer or intracranial hemorrhage * a high risk of bleeding (blood coagulation disorder, uncontrolled severe hypertension, active bleeding, or history of severe bleeding) * pregnant or lactating women * women with childbearing potential who were not using an appropriate contraception method * had medical or mental contra-indications to the study treatment